Madrigal Pharmaceuticals (MDGL) PT Raised to $375 at Oppenheimer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. SPY
3. ANT
4. META
5. FICO
6. LLY
7. TSLA
8. SPCX
9. MSFT
10. AZN

Go back to Madrigal Pharmaceuticals (MDGL) PT Raised to $375 at Oppenheimer

Madrigal Pharmaceuticals (MDGL) PT Raised to $405 at Evercore ISI, 'well positioned to execute on the launch of Rezdiffra'

March 19, 2024 2:50 PM EDT

Evercore ISI analyst Liisa Bayko raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $405.00 (from $325.00) while maintaining a Outperform rating.

The analyst comments "With clean label in hand & an additional $600M in the bank, Madrigal is well positioned to execute on the... More

Citi Closes 30-Day Upside Catalyst Watch on Madrigal Pharmaceuticals (MDGL)

March 18, 2024 4:04 PM EDT

Citi analyst David Lebowitz reiterated a Buy rating and $389.00 price target on Madrigal Pharmaceuticals (NASDAQ: MDGL).

The analyst comments "We are closing our Catalyst Watch for Madrigal following the approval of Rezdiffra (resmetirom) for the treatment of noncirrhotic nonalcoholic steatohepatitis (NASH, also known as metabolic... More